Recent acquisitions by big pharma and biotech startups highlight a trend: many innovative drugs originate from China. Foresite Capital, a venture capital firm, has actively sourced these assets since 2019, facing intensified competition from both biotech firms and large pharmaceutical companies. Foresite’s strategy includes incubating Chinese-developed drugs using AI to analyze genomic data for drug targets. The firm’s focus areas are oncology and immunology, with significant investments in AI-driven drug discovery. China’s biotechnology landscape has flourished due to substantial funding and skilled scientists, positioning it as a key player in global biotech innovation.